Cabaletta Bio, Inc. (CABA) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$2.55

From 52W high−38.55%

Volume12.39M

Market cap$432.34M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$2.55

From 52W high

−38.55%

Volume

12.39M

Market cap

$432.34M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.3x

P/E (TTM)

—

RSI (14)

38.1

MomentumView details →

1D Return

−1.16%

YTD Return

+15.75%

SummaryUpdated Jun 1, 2026

Cabaletta Bio, Inc. (NASDAQ:CABA) is a clinical-stage biotechnology company founded in 2017 and headquartered in Philadelphia, Pennsylvania. Originally incorporated as Tycho Therapeutics, Inc., the company changed its name to Cabaletta Bio in August 2018 and went public in October 2019. Cabaletta focuses on developing engineered T cell therapies specifically designed to treat B cell-mediated autoimmune diseases, representing a novel approach in the rapidly evolving field of cellular immunotherapy.

Ask drillr about Cabaletta Bio, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.3x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.1x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−86.10%

ROA (TTM)

−70.63%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+42.34%

FCF YoY

−45.14%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+29.91%

EBITDA YoY

−25.63%

MomentumView details →

1D Return

−1.16%

YTD Return

+15.75%

1Y Return

+15.75%

RSI (14)

38.1

vs 50D SMA

−12.27%

vs 200D SMA

−13.46%

Capital & dividendView details →

Debt/Equity

0.12x

Current Ratio

5.79x

Quick Ratio

5.79x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.34

EPS Surprise

8.82%

Beats (12Q)

5/12

Next Q EPS Est

−$0.32

Avg Surprise (4Q)

5.50%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−181.32M

Op. CF (TTM)

−153.93M

Next earningsNov 9, 2026 →

Latest newsMore news →

Cabaletta Bio reported a net loss of $51.0 million for Q2 2026, with diluted EPS of -$0.34, and cash and investments of approximately $225.1 million as of June 30, 2026, expected to fund operations through mid-2027.39d ago

Similar companies

Opus Genetics, Inc.IRD Atea Pharmaceuticals, Inc.AVIR Zura Bio LimitedZURA Cutia Therapeutics02487.HK Relmada Therapeutics, Inc.RLMD Uni-Bio Science Group Limited00690.HK Find similar companies →

Latest newsMore news →